Press Releases

PTC Therapeutics Announces the Initiation of a Phase 2/3 Clinical Trial to Evaluate PTC299 for the Treatment of COVID-19

PTC Therapeutics, Inc. announced that the U.S. FDA has authorized the initiation of a Phase 2/3 trial to investigate PTC299, a dihydroorotate dehydrogenase (DHODH) inhibitor, as a potential treatment for COVID-19. PTC299 is an oral investigational drug with a...

Calypso Biotech Completes CALY-002 Clinical Batch Manufacturing

AGC Biologics, a global biopharmaceutical Contract Development Manufacturing Organization (CDMO), produces a GMP-grade clinical batch of CALY-002 for Calypso Biotech. The immunotherapy biotech company retained the services of AGC Biologics for the development of the manufacturing process and the...

Glenmark becomes the first pharmaceutical company in India to receive regulatory approval for oral antiviral Favipiravir, for the treatment of mild to moderate COVID-19

In a landmark development for COVID-19 patients in India, Glenmark Pharmaceuticals, a research-led, integrated global pharmaceutical company, announced the launch of antiviral drug Favipiravir (brand name FabiFlu®) for the treatment of mild to moderate COVID-19 patients. Glenmark has received...

Sharp Expands Commercial Packaging Capabilities to UK Facility

Sharp, part of UDG Healthcare plc, a global leader in contract packaging and clinical supply services, has invested £1 million in a commercial expansion project at its site in Rhymney, UK. Since the Rhymney facility opened in late-2019 as a...

EDQM provides COVID-19 vaccine developers with free access to quality standards applicable in Europe

The EDQM is committed to supporting vaccine developers during the coronavirus disease (COVID-19) pandemic – as well as contributing to the wider global effort to combat the virus – by openly sharing knowledge and offering temporary free access to...

Imperial College London to begin human testing of new Covid-19 vaccine

The study will be the first time Imperial’s vaccine has been trialled in humans and will assess whether it is well-tolerated and produces an effective immune response against Covid-19. The trial will recruit 300 healthy participants who will then receive...

Jazz Pharma Gets Approval for Zepzelca in the U.S. for Aggressive Lung Cancer

The U.S. FDA approved Jazz Pharmaceuticals and its partner PharmaMar’s Zepzelca (lurbinectedin) for adults with metastatic small cell lung cancer (SCLC) whose disease has progressed on or after platinum-based chemotherapy. The drug was approved under accelerated approval based on...

Subscribe

- Never miss a story with notifications

- Gain full access to our premium content

- Browse free from any location or device.

Must read